ACE Stock Overview
A biotech company, focuses on orphan oncology treatments in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Ascelia Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.00 |
| 52 Week High | SEK 17.98 |
| 52 Week Low | SEK 2.00 |
| Beta | 0.98 |
| 1 Month Change | 10.70% |
| 3 Month Change | 24.74% |
| 1 Year Change | -16.43% |
| 3 Year Change | -89.53% |
| 5 Year Change | -87.18% |
| Change since IPO | -87.94% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?
Nov 09
Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?
May 31Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?
May 11Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans
Aug 05We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
Jan 24We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
Aug 23Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth
May 19Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like
Mar 07Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares
Dec 09We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
Nov 26Shareholder Returns
| ACE | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -11.5% | 1.2% | -2.7% |
| 1Y | -16.4% | 13.8% | 4.6% |
Return vs Industry: ACE underperformed the Swedish Biotechs industry which returned 13.8% over the past year.
Return vs Market: ACE underperformed the Swedish Market which returned 4.6% over the past year.
Price Volatility
| ACE volatility | |
|---|---|
| ACE Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: ACE's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ACE's weekly volatility has decreased from 16% to 9% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 13 | Magnus Corfitzen | www.ascelia.com |
Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. The company identifies, develops, and commercializes novel drugs to address unmet needs for rare cancer conditions. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 trial for the treatment of gastric cancer.
Ascelia Pharma AB (publ) Fundamentals Summary
| ACE fundamental statistics | |
|---|---|
| Market cap | SEK 288.32m |
| Earnings (TTM) | -SEK 62.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.6x
P/E RatioIs ACE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACE income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 62.30m |
| Earnings | -SEK 62.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 07, 2025
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 24.4% |
How did ACE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 00:40 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ascelia Pharma AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lars Hevreng | Danske Bank |
| Ludvig Svensson | Penser Access |
| Johan Unnerus | Redeye |